Working… Menu

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04105374
Recruitment Status : Withdrawn (NCI approval withdrawn)
First Posted : September 26, 2019
Last Update Posted : March 24, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NRG Oncology

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : November 30, 2025
Estimated Study Completion Date : November 30, 2030